All In Biotech

Drug Trial Radar · NCT02511340

A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients

Last checked: Nov 19, 2026Latest source record: Jul 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

167

Planned (sponsor's estimate)

Start

Jan 2013

Primary completion

Aug 2015

Study completion Dec 2015

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • Flumatinib mesylate tablet 600 mg qdDrug

    Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed overall hematologic response(OHR)at 6 monthsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital Tongji Medical College Huazhong University of Science and technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.